166 related articles for article (PubMed ID: 21854357)
1. Current and future medical therapy, and the molecular features of adrenocortical cancer.
Hubalewska-Dydejczyk A; Jabrocka-Hybel A; Pach D; Gilis-Januszewska A; Sokołowski G
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):132-45. PubMed ID: 21854357
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
3. The challenge of developmental therapeutics for adrenocortical carcinoma.
Costa R; Carneiro BA; Tavora F; Pai SG; Kaplan JB; Chae YK; Chandra S; Kopp PA; Giles FJ
Oncotarget; 2016 Jul; 7(29):46734-46749. PubMed ID: 27102148
[TBL] [Abstract][Full Text] [Related]
4. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract][Full Text] [Related]
5. MECHANISMS OF ENDOCRINOLOGY: Cell cycle regulation in adrenocortical carcinoma.
Pereira SS; Monteiro MP; Bourdeau I; Lacroix A; Pignatelli D
Eur J Endocrinol; 2018 Aug; 179(2):R95-R110. PubMed ID: 29773584
[TBL] [Abstract][Full Text] [Related]
6. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
7. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
[TBL] [Abstract][Full Text] [Related]
8. Gene-expression profiling of adrenocortical carcinoma.
Suh I; Guerrero MA; Kebebew E
Expert Rev Mol Diagn; 2009 May; 9(4):343-51. PubMed ID: 19441174
[TBL] [Abstract][Full Text] [Related]
9. New targeted therapies for adrenocortical carcinomas.
Manso J; Pezzani R
Minerva Endocrinol; 2019 Mar; 44(1):70-81. PubMed ID: 29808641
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of adrenocortical tumor formation and potential pharmacologic targets.
Rauschecker M; Stratakis CA
Minerva Endocrinol; 2012 Jun; 37(2):133-9. PubMed ID: 22691887
[TBL] [Abstract][Full Text] [Related]
11. 5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma.
Hoff AO; Berruti A
Horm Cancer; 2016 Feb; 7(1):29-35. PubMed ID: 26728470
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
Costa R; Wesolowski R; Raghavan D
BJU Int; 2011 Nov; 108(10):1546-54. PubMed ID: 21883840
[TBL] [Abstract][Full Text] [Related]
13. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
14. Genetics of Adrenocortical Development and Tumors.
Lodish M
Endocrinol Metab Clin North Am; 2017 Jun; 46(2):419-433. PubMed ID: 28476230
[TBL] [Abstract][Full Text] [Related]
15. The role of molecular profiling in adrenocortical carcinoma.
Lippert J; Fassnacht M; Ronchi CL
Clin Endocrinol (Oxf); 2022 Oct; 97(4):460-472. PubMed ID: 34750847
[TBL] [Abstract][Full Text] [Related]
16. Update on adrenocortical carcinoma management and future directions.
Varghese J; Habra MA
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):208-214. PubMed ID: 28277340
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
[TBL] [Abstract][Full Text] [Related]
18. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
19. The genetics of adrenocortical tumors.
Espiard S; Bertherat J
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):311-34. PubMed ID: 26038203
[TBL] [Abstract][Full Text] [Related]
20. Adrenocortical cancer (ACC) - literature overview and own experience.
Dworakowska D; Drabarek A; Wenzel I; Babińska A; Świątkowska-Stodulska R; Sworczak K
Endokrynol Pol; 2014; 65(6):492-502. PubMed ID: 25554619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
